Two obscure US biotech and medtech names – Galecto Inc (NASDAQ: GLTO) and Movano Inc (NASDAQ: MOVE) – stunned markets today with explosive rallies, each surging roughly 300%.
While the gains were triggered by company-specific news, the magnitude of the moves has drawn speculative interest from retail traders and momentum chasers.
Beneath the surface, however, questions linger about sustainability, institutional support, and long-term fundamentals.
Here’s what drove GLTO and MOVE shares higher today, and what lies ahead for both.
What drove GLTO stock higher on Monday?
Galecto shares more than quadrupled on November 10th after announcing an acquisition of Damora Therapeutics – a privately held biotech firm focused on mutant calreticulin-driven blood cancers.
The deal expands GLTO pipeline with promising monoclonal antibody therapies and was coupled with massive $285 million private placement led by top-tier investors like Viking, Wellington, and Andreessen Horowitz.
Additionally, it extends Galecto’s financial runway into 2029 – supporting multiple Phase 1 trials.
With a lead candidate targeting a rare subset of myeloproliferative neoplasms, the company is now positioned as a serious player in hematology oncology.
The GLTO stock price rally today reflects investor enthusiasm for the pipeline’s potential and the credibility of its new backers.
What drove Movano stock higher on Monday?
Movano stock nearly quadrupled today announcing a merger with Corvex – an AI cloud computing firm specializing in GPU-accelerated infrastructure.
The deal transforms Movano into a pure-play AI infrastructure platform, giving investors exposure to Corvex’s “Amplified AI Cloud™”, a solution that targets scale, efficiency, and security in high-performance inference workloads.
Movano and Corvex have raised $40 million in concurrent private placements as well – improving flexibility to fund growth initiatives.
In short, the post-merger transformation and extended runway materially boosts MOVE’s growth potential and provides investors with direct exposure to a rapidly expanding, high-value market.
At the time of writing, MOVE shares are still trading more than 70% below their year-to-date high, though.
Momentum chasing: a dangerous game in penny stocks
While GLTO and MOVE delivered eye-popping gains today, chasing such rallies typically ends in regret.
Why? Because ahead of these news, both Galecto and Movano were penny stocks.
Penny stocks are widely known to be unusually vulnerable to manipulation, pump-and-dump, and algorithmic volatility.
They lack institutional coverage, making it harder for investors to assess real value or risk.
Latecomers to meme-style rallies, like the ones that Galecto and Movano stocks experienced today, often end up buying near the top, only to watch prices crash as early traders exist.
Both MOVE and GLTO shares trade on thin volume and have limited analyst oversight, which increases the risk of sharp reversals.
Simply put, without sustained news flow or earnings traction, momentum alone is rarely enough.
Traders should, therefore, tread carefully in Galecto and Movano – what looks like a rocket could quickly turn into a trap.
The post GLTO, MOVE: two penny stocks quadrupled today – but should you buy? appeared first on Invezz
